Welcome to our dedicated page for Airsculpt Technologies SEC filings (Ticker: AIRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for AirSculpt Technologies, Inc. (NASDAQ: AIRS), a national provider of premium body contouring procedures. Through these documents, investors can review how the company reports its financial condition, operating results, governance changes and capital markets activity.
AirSculpt’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q contain audited and interim financial statements, management’s discussion and analysis, detailed risk factors and information about its single operating segment focused on direct medical procedure services. These filings also discuss the company’s use of non-GAAP measures such as Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and Adjusted Net Income per Share, along with reconciliations to GAAP metrics.
Current reports on Form 8‑K disclose material events, including quarterly earnings releases, updates to revenue and Adjusted EBITDA guidance, leadership and board changes, executive employment terms, resignations of officers, and capital structure developments. Recent 8‑K filings, for example, describe the appointment of a new Chief Financial Officer, the election of a Non-Executive Chairman of the Board, executive and board departures, and the announcement of quarterly results.
For those monitoring ownership and compensation, proxy materials and, where applicable, insider transaction reports on Form 4 can provide additional insight into equity awards, performance-based restricted stock units and other elements of the company’s equity incentive plans as referenced in its filings.
Stock Titan enhances this filings feed with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand changes in guidance, capital structure, risk disclosures and governance arrangements. Filings are updated in near real time as they are posted to EDGAR, allowing investors, analysts and other stakeholders to follow AirSculpt’s regulatory reporting history and evaluate AIRS stock using primary source information.
AirSculpt Technologies reported weaker 2025 results but a stronger fourth quarter and issued 2026 guidance. Full-year 2025 revenue fell 15.8% to $151.8 million, with case volume down 15.6% to 11,852. The company posted a net loss of $11.7 million versus $8.0 million in 2024, while Adjusted EBITDA declined to $15.1 million from $21.0 million.
Fourth-quarter trends improved, with revenue of $33.4 million, a smaller net loss turning into net income of $1.3 million, and Adjusted EBITDA rising to $2.5 million, lifting margin to 7.4% from 4.9%. Same-center revenue per case grew modestly despite lower case counts.
For 2026, the company guides to revenue of $151–$157 million and Adjusted EBITDA of $15–$17 million. As of December 31, 2025, AirSculpt held $8.4 million in cash and $56.0 million of gross debt, later reduced to about $45.0 million after raising $14.8 million through an at-the-market equity program and repaying $11.0 million of debt.
AirSculpt Technologies, Inc. operates a network of 31 centers across 20 U.S. states and Canada offering its proprietary, minimally invasive AirSculpt® body contouring procedures. The company targets elective, 100% private-pay fat removal, fat transfer and skin tightening in a spa-like setting.
In 2025, AirSculpt performed 11,852 procedures and generated $151.8 million of revenue, down from $180.4 million in 2024, a decline of about 15.8%. Average revenue per case was $12,809, supported by upfront payment and extensive use of third-party patient financing.
The business emphasizes patented technology, brand-driven digital marketing, and selective recruitment of surgeons through affiliated Professional Associations. Management highlights long-term growth strategies focused on restoring same-center revenue growth, optimizing marketing spend, expanding financing options and, over time, opening additional centers while managing regulatory, competitive and macroeconomic risks.
Airsculpt Technologies, Inc. 10% owner Jorey Chernett reported mixed option trades and a stock purchase. On March 23, 2026, he bought 50,000 shares of Airsculpt common stock in the open market at a weighted average price of $2.91 per share, bringing his direct common stock holdings to 6,843,761 shares.
He actively traded call options on Airsculpt that same day. He bought 2,255 call option contracts with a $2.00 strike at $1.30 each, then sold 6,547 of those contracts at a weighted average price of $1.13, ending with none of that series. He also purchased 2,004 call option contracts with a $4.00 strike at $0.50 and 2,000 call option contracts with a $5.00 strike at $0.33, leaving those positions outstanding.
A footnote states the sale of the $2.00 strike call options is a matchable transaction under Section 16(b), and that Chernett has calculated a short-swing profit that he intends to disgorge to Airsculpt.
Airsculpt Technologies, Inc. major shareholder Jorey Chernett reported an open-market purchase of 40,000 shares of common stock at a weighted average price of $2.77 per share. After this transaction, he directly owns 6,793,761 shares, indicating a small increase in an already large position.
Airsculpt Technologies, Inc. Chief Executive Officer Yogesh Jashnani reported a routine tax-withholding transaction related to equity compensation. On the vesting of 97,529 restricted stock units, the company withheld 38,379 shares of common stock at $2.79 per share to cover $107,076.96 of taxes. Following this non‑market disposition, he continues to hold 458,380 shares of common stock directly.
Airsculpt Technologies, Inc. ten percent owner Jorey Chernett purchased common stock in the open market. He bought 77,702 shares at a weighted average price of $2.64 per share, with individual trade prices ranging from $2.49 to $2.70. Following these purchases, he directly owns 6,753,761 shares of common stock.
Airsculpt Technologies, Inc. filed an initial ownership report for its General Counsel, Brent R. Wadman, on Form 3. The filing identifies him as an officer of the company but does not list any reportable transactions, derivative positions, or specific share holdings in this disclosure.
Airsculpt Technologies, Inc. ten percent owner Jorey Chernett reported an open-market purchase of 83,000 shares of Common Stock at a weighted average price of $2.56 per share on March 17, 2026. Following this trade, Chernett directly owns 6,676,059 shares.
The filing notes the price is a weighted average, with individual purchase prices ranging from $2.43 to $2.70 per share. It also corrects a prior Form 4, which had under‑reported Chernett’s beneficial ownership by 1,000 shares due to a clerical error.
Airsculpt Technologies, Inc. insider Jorey Chernett purchased 105,848 shares of Common Stock in an open-market transaction. The weighted average purchase price was $2.43 per share, with individual trades executed between $1.93 and $2.79 per share. After this transaction, Chernett directly owns 6,592,059 shares.
Airsculpt Technologies, Inc. receives an amended Schedule 13G showing Parian Ultreia beneficially owns 5,988,585 shares of AirSculpt Technologies, representing 9.59% of the class as reported in the filing. The filing states sole voting and dispositive power over those 5,988,585 shares.